quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:50:12·63d
INSIDERFiling
Lexicon Pharmaceuticals Inc. logo

Director Artal Participations S.A R.L. was granted 41,290 units of Series B Convertible Preferred Stock (SEC Form 4)

LXRX· Lexicon Pharmaceuticals Inc.
Health Care
Original source

Companies

  • LXRX
    Lexicon Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 5UpdateLeerink Partners$1.00
  • Jun 17UpdateH.C. Wainwright$10.00
  • Apr 30UpdateLeerink Partners$5.00
  • Mar 7UpdateJefferies$3.00
  • Aug 12UpdatePiper Sandler$10.00

Related

  • PR7d
    Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
  • PR31d
    Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
  • SEC38d
    SEC Form DEFA14A filed by Lexicon Pharmaceuticals Inc.
  • SEC38d
    SEC Form DEF 14A filed by Lexicon Pharmaceuticals Inc.
  • PR44d
    Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
  • SEC49d
    SEC Form 10-K filed by Lexicon Pharmaceuticals Inc.
  • SEC50d
    Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR50d
    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022